Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter.
A leading advocacy group petitioned the U.S. Food and Drug Administration to ban direct-to-consumer advertising of prescription medicines, a move that comes as the Trump administration leans on drugmakers to provide more balanced information in their ads.
In arguing its case, Public Citizen maintained that director-to-consumer, or DTC, ads often “mislead consumers because they are designed to persuade rather than to inform or educate patients.” The ads sometimes “employ emotional manipulation techniques or visual distractions to highlight information about benefits” while minimizing risks.
The advocacy group hopes to persuade the FDA after the Trump administration last September announced a “crackdown” on what it called deceptive drug advertising. At the time, the administration disclosed plans for new rules and stronger enforcement, which followed dozens of letters sent to companies regarding problems with their ads.
STAT+ Exclusive Story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
Individual plansGroup plans
To read the rest of this story subscribe to STAT+.